Baird lowered the firm’s price target on Biohaven (BHVN) to $57 from $60 and keeps an Outperform rating on the shares. The firm said the MAA withdrawal is not as important as the Elamipretide PDUFA.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Biohaven Ltd. Receives Buy Rating Amid Strategic EU Resubmission and Positive FDA Outlook
- Biohaven share price undervaluing pipeline potential, says RBC Capital
- Biohaven down 12% to $20.60 after pulling European application
- Biohaven trading resumes
- Biohaven withdraws troriluzole marketing application in Europe